NCT06944444View on ClinicalTrials.gov

A Phase I Clinical Study of SSS59 Monotherapy in Patients With Advanced Malignant Tumors

PHASE1RecruitingINTERVENTIONAL

Enrollment

154

Participants

Timeline

Start Date

April 27, 2025

Primary Completion Date

March 1, 2027

Study Completion Date

December 31, 2027

Conditions

Malignant Tumors

Interventions

DRUG

SSS59

A humanized antibody targeting MUC17

Trial Locations (1)

Unknown

RECRUITING

Shanghai First People's Hospital, Shanghai

All Listed Sponsors

lead

Shenyang Sunshine Pharmaceutical Co., LTD.

INDUSTRY